Intas Pharma bags CDSCO panel nod to study Human Normal Immunoglobulin
Advertisement
Pharmaceutical major Intas Pharma has got the go-head from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct the Phase III Clinical Trial of immunizing agent Human Normal Immunoglobulin for Intravenous Administration IP/EP, 5% and 10% Solution.
However, the permission is conditional upon the submission of a principal investigator (PI) undertaking and the requirement that the clinical trial sites be geographically dispersed
For more details, check out the full story on the link below:
Intas Pharma Gets CDSCO Panel Okay To Study Human Normal Immunoglobulin
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.